Drugs that contain Dexlansoprazole
1. List of Dexilant drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(2 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6664276
(Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(3 months from now) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months from now) | |
| US8722084 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months from now) | |
|
US8784885
(Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(1 year, 13 days from now) | |
|
US8722084
(Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(1 year, 13 days from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(2 years from now) | |
|
US8461187
(Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(3 years from now) | |
| US7790755 | TAKEDA PHARMS USA | Controlled release preparation |
Aug, 2026
(3 years from now) | |
| US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(3 years from now) | |
|
US7790755
(Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(3 years from now) | |
|
US8105626
(Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(3 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(4 years from now) | |
| US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(6 years from now) | |
|
US8173158
(Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(7 years from now) | |
| US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(8 years from now) | |
Market Authorisation Date: 30 January, 2009
Treatment: For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); To maintain healing of ee and relief of heartburn; For healing of all grades of erosive esophagi...
Dosage: CAPSULE, DELAYED RELEASE;ORAL
DEXILANT family patents
35
United States
23
Japan
12
European Union
9
Korea, Republic of
8
Canada
7
Argentina
7
Spain
6
China
5
Denmark
5
Australia
5
Brazil
5
Portugal
5
Cyprus
4
Mexico
4
Hong Kong
4
Malaysia
4
Taiwan, Province of China
3
Israel
3
Russia
3
Norway
3
Costa Rica
3
Peru
3
Poland
3
New Zealand
2
South Africa
2
Slovenia
2
Singapore
1
OA
1
Austria
1
Belgium
1
Hungary
1
Morocco
1
Germany
1
Colombia
1
Chile
2. List of Dexilant Solutab drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(2 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6664276
(Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(3 months from now) | |
| US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months from now) | |
|
US8784885
(Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(1 year, 13 days from now) | |
| US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(2 years from now) | |
| US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(2 years from now) | |
|
US8461187
(Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(3 years from now) | |
| US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(4 years from now) | |
|
US8871273
(Pediatric) | TAKEDA PHARMS USA | Method for producing granules |
Jul, 2028
(5 years from now) | |
| US9241910 | TAKEDA PHARMS USA | Orally-disintegrating solid preparation |
Mar, 2029
(5 years from now) | |
Market Authorisation Date: 26 January, 2016
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
DEXILANT SOLUTAB family patents
30
United States
21
Japan
10
European Union
8
Argentina
7
Korea, Republic of
7
Canada
5
Australia
5
Brazil
5
Spain
5
Peru
5
Taiwan, Province of China
5
China
4
Mexico
4
Costa Rica
4
Malaysia
4
New Zealand
3
South Africa
3
Denmark
3
Hong Kong
3
Norway
3
Portugal
3
Cyprus
3
Poland
2
Israel
2
Slovenia
2
Morocco
2
Chile
1
OA
1
Austria
1
Belgium
1
Hungary
1
Uruguay
1
Germany
1
Colombia
1
Singapore
1
Dominican Republic
1
Ecuador
1
Georgia
1
Ukraine
1
EA
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic